Change has been the one constant in nuclear medicine from the beginning, with the steady arrival of new radiopharmaceuticals, new technologies and an evolving regulatory environment.
Today, as nuclear medicine expands rapidly beyond diagnostics and into novel therapies personalized for individual patients, there is greater complexity and an even faster rate of change.
Theranostics and precision health care hold much promise for improving patients’ lives, but nuclear medicine departments face challenges in adopting new theranostics and ensuring patient access. In this complex, rapidly changing industry, the experts at Cardinal Health Nuclear & Precision Health Solutions have been providing trusted advice and guidance for more than 40 years, helping nuclear medicine departments prepare for and embrace the future. For example:
- Cardinal Health established the first-ever commercial centralized nuclear pharmacy in 1972;
- Cardinal Health created the first nationwide radiopharmacy network in 1982;
- Cardinal Health opened the first commercial positron emission tomography (PET) cyclotron in 1992;
- Cardinal Health completed the purchase of LYMPHOSEEK in 2017.
Read more about what Cardinal Health is doing to advance nuclear medicine in this new white paper authored by Mike Pintek, senior vice president of Cardinal Health Nuclear & Precision Health Solutions.